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Summary 
Cross-presentation is the process by which professional Antigen Presenting Cells (APCs) 
are able to load peptides from an extracellular processed protein into class I molecules, 
triggering a CD8
+
 T cells response. How to increase the efficiency of this process is thus an 
area
 
of great interest for the development of antitumor and antiviral vaccines which are 
required to stimulate a cytotoxic T cell response. One promising strategy is the use of 
adjuvants, molecules that are added to vaccines in order to modulate the immune response 
and increase protection.  The discovery that some compounds with adjuvant function are 
recognized by Toll like receptors (TLRs), receptors involved in
 
pathogen-associated 
molecular patterns recognition, drove the interest in developing a novel family of vaccine 
adjuvant based on triggering the TLR pathways. The aim of my PhD project is to 
investigate if the novel compound, agonist of TLR2 (SMIP2-1), can enhance cross-
presentation of soluble antigens to CD8
+
 T cells. SMIP2-1 is a novel synthetic lipopeptide, 
identified through two cell-based high throughput screens performed at the Genomic 
Institute of Novartis Research Foundation, and is currently under evaluation as vaccine 
adjuvant by Novartis Vaccines. Using mice reconstituted with Ovalbumin (OVA) specific 
OT-I TCR transgenic  cells, as well as unreconstituted wild type mice, immunized with 
OVA and SMIP2.1, we found that addition of our compound to the vaccine formulation 
increases CD8
+
 T cell proliferation, cytokines production, and cytotoxic activity, along with 
specific antibody production.  Moreover, using an OVA expressing tumor model, we show 
that the CTLs induced by the SMIP2.1 formulated vaccine are able to inhibit tumor growth 
in vivo. One mechanism by which SMIP2.1 could enhance the immunogenicity of antigens 
is its ability to increase antigen deposition in the draining lymph node of the site of 
injection, and the amount of APC that take up the antigen, as we demonstrated by confocal 
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analysis. We then identified which cells populations can cross-present in vitro and we 
found that both CD8+ and CD8- DCs are able to cross-present when stimulated with 
SMIP2.1 In order to evaluate the effect of SMIP2.1 on human cells, we used a flow 
cytometry assay to detect activation of CD8
+
 T cells isolated from human PBMC of 
Cytomegalovirus seropositive donors. We found that stimulation with SMIP2.1 is able to 
greatly increase the capacity of human APC, pulsed in vitro with the pp65 CMV protein, to 
activate CMV-specific CD8
+
 T cells. Over all our data demonstrate that vaccination with 
exogenous antigen formulated with SMIP2.1 is a successful strategy to induce a cytotoxic T 
cell response along with antibody production.  
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Sommario 
Si definisce “Cross-presentazione” il meccanismo attraverso il quale le Cellule Presentanti 
l’Antigene (APCs) sono capaci di catturare, processare e caricare sul complesso MHC di 
classe I peptidi derivanti da un antigene extracellulare, inducendo una risposta citotossica 
da parte dei linfociti  T CD8
+
. La risposta citotossica è di particolare importanza per lo 
sviluppo di vaccini antitumorali e antivirali, per i quali è necessaria un’attivazione delle 
cellule T CD8
+
. Come indurre la cross-presentazione ha quindi stimolato grande interesse 
da parte delle industrie farmaceutiche per lo sviluppo di questi vaccini.  Una strategia 
promettente è l’utilizzo di adiuvanti, molecole aggiunte ai vaccini per modulare la risposta 
immunitaria e aumentare la protezione. La scoperta che composti con funzioni adiuvanti 
legassero i recettori di tipo Toll (TLRs), recettori coinvolti nel riconoscimento di motivi 
molecolari comuni a molti microrganismi patogeni, ha sollevato l’interesse verso lo 
sviluppo di una nuova famiglia di adiuvanti basati sull’attivazione dei pathways dei TLRs. 
Lo scopo del mio progetto di Dottorato è investigare se un nuovo composto, agonista del 
TLR2 (SMIP2.1), può aumentare la cross-presentazione di un antigene esogeno alle cellule 
T CD8
+
. SMIP2-1 è un lipopeptide di sintesi, identificato attraverso uno screening 
effettuato al Genomic Institute of Novartis Research Foundation, che Novartis Vaccines 
intende utilizzare come adiuvante. Utilizzando Ovalbumina (OVA) come antigene esogeno, 
abbiamo osservato che l’immunizzazione con OVA + SMIP2.1, sia di topi transgenici con 
un TCR specifico per OVA che di topi wild type, aumenta la risposta T CD8
+
 in termini di 
proliferazione, produzione di citochine e attività citotossica, rispetto a topi vaccinati solo 
con l’antigene. Inoltre, SMIP2.1 induce un’ottima risposta anticorpale contro l’antigene, 
caratteristica fondamentale di un adiuvante. Utilizzando cellule tumorali murine che 
esprimono OVA, abbiamo osservato che la risposta citotossica indotta dall’agonista del 
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TLR2 è capace di inibire la crescita tumorale in vivo. Un meccanismo attraverso cui 
SMIP2.1 aumenta la risposta immunitaria potrebbe essere la sua abilità di aumentare la 
deposizione dell’antigene nei linfonodi drenanti sul sito di iniezione e l’uptake 
dell’antigene da parte delle APCs, come dimostrato dalle osservazioni al microscopio 
confocale. Abbiamo poi analizzato quale popolazione cellulare può cross-presentare in 
vitro, scoprendo che sia le cellule dendritiche CD8+ e CD8- sono capaci di cross-
presentare dopo stimolazione con SMIP2.1.  
Per valutare l’effetto dell’agonista del TLR2 su cellule umane, abbiamo usato un’analisi al 
citofluorimetro per misurare l’attivazione delle cellule T CD8+ isolate dai PBMC di 
pazienti positivi per il Citomegalovirus. Abbiamo trovato che SMIP2.1 aumenta la capacità 
delle APC umane, stimolate in vitro con la proteina pp65 del CMV, di attivare una 
popolazione T CD8
+
 specifica per il CMV.  
In conclusione, i nostri dati dimostrano che la vaccinazione con una proteina esogena 
formulata con SMIP2.1 è una promettente strategia per indurre sia una risposta citotossica 
che una risposta anticorpale.   
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1. Introduction 
1.1 Overview of the immune system 
We are constantly exposed to infectious agents and, in most cases, we resist these infections 
by means of our immune system that is able to mount an immune response against the 
pathogens that otherwise would cause infection. The mammalian immune system is 
comprised of two branches: innate and adaptive immunity. The innate immune system is 
our first line of defense against invading organisms while the adaptive immune system acts 
as a second line of defense and also affords protection against re-exposure to the same 
pathogen. Although both the innate and adaptive immune systems work to protect against 
invading organisms, they play different roles. The adaptive immune system requires some 
time to react to an invading organism, whereas the innate immune system includes defenses 
that, for the most part, are constitutively present and ready to be mobilized upon infection. 
Second, the adaptive immune system is antigen specific and reacts only with the organism 
that induced the response. In contrast, the innate system is not antigen specific and reacts 
equally well to a variety of organisms. Moreover, the adaptive immune system 
demonstrates immunological memory: remembering to have met a pathogen, it is able to 
react more rapidly to its following exposure. In contrast, the innate immune system does 
not demonstrate immunological memory.  
Although these two arms of the immune system have distinct functions, there is interplay 
between these systems.  
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1.1.1 The innate immunity 
The innate immunity is the first line of defense against pathogenic microbial invasion. In 
vertebrates, the skin and other epithelial surfaces, including those lining the lung and gut, 
provide a physical barrier between the inside of the body and the outside world. 
Microorganisms can occasionally pass through the epithelial barriers. It is then up to the 
immune system to identify and destroy them, without harming the host.  
Cells of the innate immune system sense infection with a variety of receptors called Pattern 
Recognition Receptors (PRRs), which are innate immune receptors extremely conserved 
throughout evolution. These receptors are able to bind and  recognize few, highly 
conserved structures expressed by a  microorganisms but not found in higher organisms, 
referred  as Pathogen-Associated Molecular Patterns (PAMPs). For this reason the innate 
immune response is not specific in terms of antigen recognition.  
Neutrophils, eosinophils, basophils, macrophages/monocytes, dendritic cells (DCs), and 
natural killer (NK) cells are the cellular components of the innate immune system. 
Phagocytic cells as macrophages, monocytes, DCs and neutrophils express PRRs. The 
recognition of PAMPs on the surface of pathogens by PRRs induces the engulfment of the 
pathogen in a phagosome where a combination of degradative enzymes, antimicrobial 
peptides, and reactive oxygen species kills the invading microorganism.  
NK cells are other important effector cells of the innate immune response. They recognize 
microbes and cells infected by viruses or intracellular bacteria in an antigen-non-specific 
manner. They function by secreting cytokines, mainly IFN-, which activates macrophages 
and other cells. NK cells can also destroy microbes or virus-infected cells by producing 
perforins and inducing the apoptosis of infected cells.  
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Other important components of innate immunity are soluble molecules, such as cytokines 
and chemokines, produced by cells of the innate system and active on cells of both the 
innate and adaptive immunity. Chemokines release favors the leukocyte mobility from the 
lymph nodes to the site of infection through the endothelial barriers. Cytokines promote the 
phagocytic ability of macrophages and neutrophils, the cytotoxic activity of NK cells and 
the differentiation and activation of T and B lymphocytes. A group of cytokines playing a 
crucial function in the innate immune response is represented by the interferon family. 
Interferons function as immunomodulators, as well as an inducer of an antiviral state in 
cells (Christensen and Thomsen, 2009; Rasmussen et al., 2009).  
Despite the lack of specificity, innate immunity is highly effective and in many cases 
sufficient to eliminate the invading agent. In other cases the innate immune response cannot 
cope with infection but through different mechanisms triggers the initiation of an adaptive 
immune response.  
 
1.1.1.1 Toll-like receptors 
Toll-like receptors (TLRs) are among the best studied PRRs (Franchi et al., 2009) 
(Takeuchi and Akira, 2009). These components of the innate immune response recognize 
pathogen-derived molecules, ranging from bacterial and yeast cell wall components to viral 
and bacterial nucleic acids including lipopolysaccharide (LPS) of gram-negative bacteria, 
peptidoglycan of gram-positive bacteria, flagellin, lipopeptides, non-methylated CpG DNA. 
The protein Toll, German slang for ‘‘fantastic,’’ was first derived from the Toll gene of 
Drosophila, a maternal-effect gene that plays a central role in the establishment of dorsal–
ventral patterning during embryonic development (Belvin and Anderson, 1996). Moreover, 
Toll is required for Drosophila response to fungi being part of a peptidoglycan sensing 
cascade which ends in the production of antifungal peptides by cells of the fat body (Crotta 
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et al.; De Gregorio et al., 2002; Lemaitre et al., 1996).The high homology between the 
intracellular regions of Drosophila Toll and mammalian IL-1R, as well as the similarity in 
the signaling pathways triggered by these two receptors, both of which result in NF-kB 
activation, led to the hypothesis that Toll could also have a function in the mammalian 
immune response (Hoffmann, 2003; Lemaitre, 2004).  
TLRs engagement leads to the induction of various genes that function in host defense, 
including inflammatory cytokines, chemokines, major histocompatibility complex (MHC) 
and co-stimulatory molecules. TLRs are type I transmembrane proteins with an ectodomain 
containing leucine-rich repeats that mediate the recognition of PAMPs, a transmembrane 
domain and an intracellular region which contain the Toll-Interleukin 1(IL-1) receptor 
(TIR) domain required for downstream signal transduction. The TIR domain interacts with 
cytoplasmatic adaptor molecules that initiate intracellular signaling. There are four such 
adaptors in mammalian TLRs, whose activation influences which signals will be activated 
by TLRs: MyD88, TIRAP (also called MAL), TICAM1 (also called TRIF), and TICAM2 
(also called TRAM) (Figure 1). MyD88 associates with the cytoplasmic TIR domain of 
TLRs, and recruits IRAK to the receptor upon ligand binding. IRAK then activates TRAF6, 
leading to the activation of the IκB kinase (IKK) complex consisting of IKKα, IKKβ and 
NEMO/IKKγ. The IKK complex phosphorylates IκB, resulting in nuclear translocation of 
NF-κB which induces expression of inflammatory cytokines. With the exception of TLR3, 
which signals exclusively via TICAM1, all TLRs utilize a MyD88-dependent pathway 
resulting in the production of TNF-α, IL-1, IL-6, and other cytokines dependent on NF-κB. 
MyD88 also trigger mitogen-activated protein (MAP) kinase cascades that lead to 
activation of AP-1, cyclic AMP (cAMP) response element-binding protein (CREB) and the 
transcription factor interferon regulatory factor 7 (IRF7), leading to the induction of type I 
interferons (IFNs), which are especially potent anti-viral cytokines. TIRAP, the second TIR 
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domain-containing adaptor, is involved in the MyD88-dependent signaling pathway via 
TLR2 and TLR4. In TLR3- and TLR4-mediated signaling pathways, activation of IRF-3 
and induction of IFN-β are observed in a MyD88-independent manner. Third TIR domain-
containing adaptor, TRIF, is essential for the MyD88-independent pathway leading to 
activation of IRF-3 to induce type I IFNs. TRAM, is specific to the TLR4-mediated 
MyD88-independent/TRIF-dependent pathway.  
 
 
Figure1 TLR signaling pathway (Takeda and Akira, 2005) 
 
Most classes of TLRs are found in immune cells such as polymorphonuclear neutrophils, 
monocytes/macrophages, DCs, NK cells, T and B cells, where they trigger an immediate 
response against pathogens. However, accumulating evidence indicates that a number of 
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TLRs are widely expressed also in non-immune cells, such as endothelial cells, epithelial 
cells, skin keratinocytes, and fibroblasts (Pegu et al., 2008).  
Humans express ten functional TLRs (TLR1 to TLR10), whereas twelve TLRs (TLR1 to 
TLR9 and TLR11 to TLR13) have been identified in mice. Ligands have been determined 
for all TLRs except for human TLR10, mouse TLR12 and mouse TLR13.  
Studies with mice deficient for each TLR have demonstrated that they have distinct 
functions in terms of PAMP recognition and immune responses (Abe et al.). The 
intracellular localization of some members of the TLR family is believed to be important to 
restrict ligand accessibility and therefore avoid recognition of self-molecules such as 
endogenous nucleic acids. On the basis of their respective PAMP ligands and their cellular 
localization TLRs can be divided into two groups (Figure 2): 
 One group is composed of TLRs which are expressed on cell surface and recognize 
mainly microbial membrane components such as lipids, lipoproteins and proteins. This 
group includes TLR1, TLR2, TLR4, TLR5 and TLR6. TLR2 can heterodimerize with 
TLR1 or TLR6 to recognize respectively triacyl- or diacyl-lipopeptides which are 
present on the surface of many bacteria. TLR4 is specialized in responding to 
lipopolysaccharide (LPS) expressed by Gram-negative bacteria, while flagellin, a 
protein of the bacterial flagella, is recognized by TLR5.  
 The second group is composed of TLRs which are expressed exclusively in intracellular 
vesicles such as the endosplasmatic reticulum (ER), endosome, lysosome and 
endolysosomes, where they recognize microbial nucleic acids (Abe et al.). It is 
composed of TLR3, TLR7, TLR8 and TLR9. TLR3 binds double-stranded RNA, TLR7 
and TLR8 recognize single-stranded RNA while TLR9 signaling is triggered by binding 
to CpG-rich sequences which are abundant in microbial DNA.  
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Expression of TLRs is quite different among cell types. For example TLR2 and TLR4 are 
expressed on various immune cells including macrophages, DCs, B cells, granulocytes, NK 
cells and T cells. They are also expressed on non-immune cells such as fibroblasts and 
epithelial cells. TLR7 and TLR9 are largely expressed in the immune cells and in particular 
are predominantly expressed in plasmacytoid DCs. 
 
 
Figure 2. Surface (TLR1, 2, 4, 5, and 6) and intracellular (TLR3, 7, 8, and 9) localization of 
TLRs in a cell of the innate immune system. Only a few molecules out of a large variety of 
PAMPs are shown (Land, 2012).  
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1.1.1.2 Toll-like receptor 2 
TLR2 interacts with a broad and structurally diverse range of ligands, including molecules 
expressed by microbes and fungi (Abe et al., 2007). Among them there are lipopeptides, 
peptidoglycan and lipoteichoic acid from bacteria, lipoarabinomannan from mycobacteria, 
zymosan from fungi and the hemagglutinin protein from viruses. Ligand specificity as well 
as signal transduction ability of TLR2 is determined by its heterodimeric interactions with 
TLR1 and TLR6 (Ozinsky et al., 2000). Specifically, the TLR2-TLR1 heterodimer 
recognizes triacylated lipopeptides from Gram-negative bacteria, whereas the TLR2-TLR6 
heterodimer recognizes diacylated lipopeptides from Gram-positive bacteria and 
mycoplasma.  Since TLR2 is expressed on many different cell types (including dendritic 
cells, macrophages and lymphocytes) the mechanisms by which bacterial lipopeptides 
activate the immune system are diverse. Pre-clinical testing indicates that lipopeptides co-
administered with or physically linked to Ag can induce DC maturation leading to the up-
regulation of co-stimulatory signals and Ag-presenting molecules (e.g. MHC class II, 
CD80, CD83, IFN, IL-12) (Hertz et al., 2001), stimulate macrophages to release cytokines 
(e.g. TNF, IL-1, IL-6) (Muhlradt et al., 1997), promote the maturation and activation of B 
cells leading to increased production of Ag-specific IgG and IgM Abs (Borsutzky et al., 
2005) and boost the generation of antigen-specific CD8
+
 T cell (CTL) responses (Jackson 
et al., 2004) (Borsutzky et al., 2006). 
 
1.1.2 The adaptive immunity  
The adaptive immune response is antigen-specific and requires the recognition of specific 
"non-self" antigens to be activated. Adaptive immune responses are carried out by white 
blood cells called lymphocytes. There are two major lymphocytes types, B cells and T cells 
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which differ in their functionality but use structurally similar receptors to specifically 
recognize antigenic determinants. Differences in T-cell and B-cell receptors are generated 
in precursor cells through rearrangement of their respective B- and T-cell receptor gene 
segments and through a process of “somatic hypermutation”. This mechanism allows a 
small number of genes to generate a vast number of different antigen-specific receptors, 
which are then uniquely expressed on each individual B or T lymphocyte. This allows the 
body to have cells that can specifically target most of the pathogens that an organism might 
encounter during its lifetime.  
 B cells. The antigen-recognition molecules of B cells are the immunoglobulins (Ig) that 
exist in membrane-anchored or secreted forms. The membrane-bound form, known as 
the B-cell receptor (BCR), is expressed on the cell surface and work as receptor for the 
antigen. When a B cell recognizes its cognate antigen thought the BCR, the B cell 
proliferates and differentiates into terminally differentiated B cells, called plasma cells, 
able to secrete immunoglobulin of the same antigen specificity as antibody. The 
secretion of antibodies, key mediators of humoral immune response, has two separate 
functions. One is to bind specifically molecules from the pathogens, leading to their 
neutralization; the other is to recruit other cells, e.g. phagocytes, to destroy the pathogen 
once the antibody is bound to it (a process known as opsonophagocytosis). There are 
different types of antibodies, known as IgM, IgA, IgG, IgD and IgE. Each 
immunoglobulin differs in its biological proprieties and in the capability to bind 
different antigens. All B cells initially express and synthetize IgM, but may switch to 
other isotypes upon gene rearrangement, a mechanism known as isotype-switching. 
Switched isotypes are antibodies that maintain their specific antigen-recognition 
capacity but differ in other domains of the molecule that determine their functionality. 
IgA antibodies are usually present in different mucosal body fluids and are important in 
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the local infection. IgG are the most abundant immunoglobulin that are present in the 
serum and can be divided in 4 different classes in humans: IgG1, IgG2, IgG3 and IgG4. 
IgD are present on the surface of mature but not immature B lymphocytes. They bind 
the antigen and stimulate the cells to grow and differentiate in plasma cells. IgE are 
important against parasites infection, and in the autoimmune response. 
 T cells. T-cell receptors (TCRs), the antigen-recognition molecules of T cells, are 
related to immunoglobulins in their protein structure but they are made only of 
membrane-bound polypeptide chains. Unlike the BCR, the TCR does not recognize and 
bind the antigen directly, but recognizes short, linear peptide fragments of protein 
antigens, bound to transmembrane glycoproteins known as Major Histocompatibility 
Complex (MHC) molecules on the surface of cells. There are two classes of MHC 
molecule, called MHC class I and MHC class II, which differ in their structure, 
expression pattern and source of peptides that they carry to the cell surface. MHC class 
I molecules are expressed on all nucleated cells: they collect peptides derived from 
proteins synthesized in the cytosol and are thus able to display protein fragments of 
intracellular pathogens on the cell surface. MHC class II molecules are present only on 
APCs, such as DCs, B lymphocytes and macrophages. APCs are able to capture, 
process and present antigenic peptides derived from extracellular antigen.  
Once reached the cell surface with their peptide cargo, the two classes of MHC 
molecule are recognized by different functional classes of T cells: helper, cytotoxic and 
regulatory T cells. 
o Helper T cells. Antigenic peptides bound to MHC class II molecules are recognized 
by T lymphocytes marked by the cell-surface protein CD4. CD4
+
 T cells are called 
T helper (Th) cells. When a TCR expressed on a T lymphocyte recognizes the 
antigen presented on MHC II molecules on the surface of an APC, it starts an 
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activation cascade within the cell. The T cell initiates its clonal expansion, to give 
rise to a number of identical progeny cells, and starts to produce cytokines. These 
cytokines and other signals can activate additional immune cells (e.g. give help to 
antigen-specific B cells to produce antibodies against the antigen). Based on the 
types of pathogen that should be fought, T helper cells can differentiate in 3 main 
subtypes, which secrete different cytokines depending on the type of immune 
response required to eliminate the pathogen: Th1, Th2 or Th17. Th1 responses are 
involved in the cellular or cytotoxic immune response needed to eliminate 
intracellular bacteria or viruses. Th2 responses are important for the humoral 
immune response against extracellular organisms. In general the Th2 response is 
specific against large extracellular parasites or soluble antigens. The stimulation of a 
Th response causes B cell activation and therefore a humoral response with 
antibody production. Th17 fights for example fungal infections.  
o Cytotoxic T cells. MHC I molecules are recognized by T lymphocytes bearing the 
cell-surface protein CD8. CD8
+
 T cells are cytotoxic T cells (CTL) able to kill 
somatic cells that are infected with cytosolic pathogens like viruses, 
intracytoplasmic bacteria, and protozoa, but also damaged or dysfunctional cells 
like tumor cells. Cytotoxic T lymphocytes are able to release a panel of molecules, 
like two families of proteases: perforins and granzymes. Perforins form pores in the 
target cells’ plasma membrane allowing granzymes to enter the target cell and 
activate a series of proteases that eventually induce apoptosis of the infected cells. A 
second mechanism to induce apoptosis involves the recognition between the surface 
molecule FAS ligand, expressed on activated CD8
+
 T cells, to Fas molecules, 
expressed on the target cells. The binding induces a signaling cascade leading to 
apoptosis of the target cell. In addition, cytotoxic T lymphocytes are able to lead the 
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activation of different cellular pathways, including the activation of NF-B, which 
is an important factor implicated in the response to different stimuli including stress, 
cytokines, inflammation, etc. The main result of NF-B activation is the production 
of cytokines and chemokines that activate and recruit immune cells to the site of 
infection. 
o Regulatory T cells. Although the existence of cells able to suppress an immune 
response has been long postulated, their identification and characterization have 
only been recently established. Regulatory T cells (TReg) constitutively express a 
key transcription factor, known as forkhead box P3 (FOXP3), that is required for 
their development, maintenance and function (Hori et al., 2003). The major function 
of regulatory T lymphocytes is the maintenance of peripheral tolerance, preventing 
autoimmune diseases and limiting chronic inflammatory diseases by blocking the 
activity of effector, helper and APC cells. There are a lot of possible mechanisms 
used by TReg cells to mediate suppression that remain to be fully elucidated (Vignali 
et al., 2008).  
 
1.1.3 Antigen presentation mechanisms 
The initial step in the presentation of an extracellular antigen is the binding and the 
internalization of the antigen by APCs. There are different ways by which APCs can bind 
the antigen. For example, they express receptors that recognize mannose residues present in 
bacterial walls and mediate the internalization of bacteria. Macrophages also express 
specific receptors for the Fc portions of the antibodies that enhance the internalization of 
antigens with attached antibodies. After their internalization, antigen localizes in 
intracellular vesicles called endosomes that will then fuse with phagosomes, characterized 
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by an acidic pH and the presence of proteolytic enzymes. Enzymatic degradation of the 
endocytosed antigen generates peptides that can bind the peptide-binding motif of MHC II 
molecules. These molecules are synthetized in the endoplasmic reticulum with an 
associated short protein called invariant chain that, occupying the binding cleft, prevents 
the aspecific binding of self-peptides to MHC II molecules. Vesicles transporting class II 
molecules out of the ER meet and fuse the phagosome containing the processed antigen. 
The proteolitic enzymes in the endocytic vesicles remove the invariant chain so that the 
cleft becomes accessible to peptides generated by proteolysis of exogenous antigens. The 
complex MHC II molecules-peptide is then displayed on the cell surface of APC where is 
recognized by specific CD4
+
 T cells.   
MHC class I-presented peptides are derived from intracellular proteins. Foreign antigens in 
the cytosol may be proteins derived from viruses or other microbes that infect nucleated 
cells and synthetize their own proteins in the cytosol of host cells, or they can derive from 
mutated genes in tumor cells. These proteins are degraded by the proteasome, a large 
multiprotein enzyme complex, with proteolitic activites, found in the cytoplasm of cells. 
Peptides derived from proteasome degradation are transported through the transporter 
associated with antigen processing (TAP) in the endoplasmic reticulum, where newly MHC 
class I molecules are synthesized. The MHC class I complex binds the peptide; the 
peptide/MHC complex is transported through the Golgi apparatus to the cell surface by 
exocityc vesicles. Once expressed on the cell surface, the peptide/MHC I complex may be 
recognized by antigen specific CD8
+
 T cells. 
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1.1.4 Cross-presentation 
Since the mid-80s, it was accepted that peptide derived from degradation of endogenous 
protein in the cytosol of APCs  were loaded into MHC class I molecules , while MHC class 
II molecules presented peptides derived from exogenous antigens degraded  within the 
endocytic route. The MHC class I presentation of endogenous antigen by professional APC 
to elicit an immune response is also called direct presentation. If only the direct pathway 
exists for MHC class I, then how can cytotoxic T lymphocyte (CTL) responses be elicited 
against tumor cells of non-haematopoietic origin or against viruses that do not infect 
professional APC? 
This enigma was resolved when Bevan showed that CTL responses could also be elicited 
against antigens derived from an exogenous source (Bevan, 1976). He showed that minor 
histocompatibility antigens could be transferred from donor cells to host APCs and termed 
the resultant T-cell priming ‘cross-priming’. Thus, the term ‘cross-presentation’ has been 
used to encompass when presentation of an exogenous antigen results in activation (cross-
priming) or tolerization (cross-tolerance) of CD8
+
 T cells. 
Cross-presentation is the mechanism by which peptides derived from intracellular 
phagocytosed antigens can be presented by APC on MHC class I molecules, leading to 
CD8
+
 T cells activation (Bevan, 1976) (Rock and Shen, 2005). The mechanisms underlying 
cross-presentation are not so clearly understood; however different pathways have been 
proposed.  
 TAP-independent pathway: Antigens could be degraded by endosomal proteases, for 
example cathepsins, and subsequently be loaded onto MHC I molecules within 
endosomes (Figure 3a). This model should not require the transporter associated with 
antigen processing (TAP), and has been referred to as TAP-independent pathway. 
However, most studies examining the cell biology of cross-presentation reported a 
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requirement of TAP and the proteasome (Burgdorf et al., 2007) (Ackerman et al., 
2006). 
 TAP-dependent pathway: The canonical model states that antigen uptake into 
endosomes is followed by translocation of internalized antigens from endosomes to the 
cytosol of the APCs (Figure 3b). In the cytosol, proteins are degraded by the 
proteasome complex, and TAP shuttles the resultant peptides into the endoplasmic 
reticulum (ER) for MHC class I loading before being transported into the lumen of the 
(ER) for presentation at the cell surface. This model, also referred as TAP-dependent 
pathway, is further supported by data showing that cross-presentation is increased by 
the inhibition of lysosomal acidification with the drug chloroquine, indicating that these 
peptides were generated in non-lysosomal compartments (Bertholet et al., 2006). 
 TAP-dependent within endosomes pathway: Third, antigen-derived peptides might be 
reimported from the cytoplasm into early endosomes, and MHC I loading might occur 
there (Figure 3c). This of course would require the presence of the MHC I-loading 
machinery in these endosomes. 
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Figure 3: Putative intracellular mechanisms of cross-presentation. (Burgdorf and Kurts, 2008) 
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1.2 Vaccines 
1.2.1 Principle of vaccination 
Vaccination is one of the most successful public health interventions in modern history and 
has dramatically reduced damage and death caused by infectious diseases.  Vaccines are 
biological products that mimic an infectious agent without causing the disease. The goal of 
vaccination is to generate a strong immune response of sufficient duration and magnitude to 
the administered antigen in order to stimulate an immunological memory to prevent 
infection and reduce the related pathology. Although classically represented by attenuated 
or killed microorganisms, modern vaccines more often comprise pathogen-derived 
components or recombinant proteins that represent safer and cost-saving formulations.  
However, a series of clinical and experimental observations have clearly illustrated the 
reduced immunogenicity of subcellular or subunit-based vaccines when compared with 
inactivated/killed whole organisms. The weak immunogenicity of soluble proteins, lacking 
the inherent danger-signature often associated with a pathogen, appears to be related to 
their inability to induce DCs maturation representing the limiting step in the development 
of efficient vaccines. The challenge for modern vaccinology is therefore to be able to elicit 
in vivo all the required steps that lead to immune activation. This limitation could be 
overcome by the use of adjuvants. 
 
1.2.2 Adjuvants 
Successful vaccines should contain not only a protective antigen, but also a good adjuvant 
(Coban et al., 2007). The term “adjuvant” derives from the Latin “adjuvare”, meaning to 
help. The purpose of adjuvants in vaccine formulations is to help the function of the 
immune system so that a coadministered microorganism or protein or polysaccharide 
becomes more immunogenic. Thus adjuvants can be defined as molecules acting 
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independently of an antigen in order to directly activate, increase and/or modulate innate 
and/or adaptive immune cells. They can promote humoral or cellular immunity, influence 
the cytokine polarity of T-helper cell responses, and promote a local or systemic immune 
response. Adjuvants can also help inducing stronger immune responses with fewer 
injections, and consequently improving both the feasibility and success rate of large-scale 
population vaccine campaigns in developing countries (Rappuoli, 2007). Vaccine adjuvants 
are represented by different classes of compounds such as microbial products, mineral salts, 
emulsions, microparticles, and liposomes. The mechanism of action of many adjuvants has 
been long investigated. Recent studies suggest that the formation of Ag depots, that prolong 
the persistence of Ag in vivo, and the activation of inflammation by various innate cells are 
components dictating the success of an adjuvant (Coban et al., 2007) (Seubert et al., 2008) 
(Lambrecht et al., 2009). 
Adjuvants can be classified according to their component sources, physiochemical 
properties or mechanisms of action. Two classes of adjuvants commonly found in modern 
vaccines include immunopotentiators and delivery systems.  
Immunopotentiators directly act on the immune system to increase responses to antigens. 
Examples include: TLR ligands, cytokines, glycolipids that alter antigen processing, 
saponins and bacterial exotoxins, all of them able to stimulate immune responses.  
Delivery systems have the ability of presenting vaccine antigens to the immune system in 
an optimal manner, including controlled release of the antigen in order to increase the 
specific immune response. Indeed, this class of adjuvants is able to modulate antigen 
persistency or antigen uptake by different populations of APCs. They can also serve to 
deliver the immunopotentiators described previously. Examples include: mineral salts, 
emulsions, liposomes, virosomes (nanoparticles made of viral proteins such as influenza 
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hemagglutinin and phospholipids), biodegradable polymer microspheres and so-called 
immune stimulating complexes (i.e. ISCOM, ISCOMATRIXTM
TM
). 
Of the many experimental adjuvants currently available, only aluminum-based salt and 
squalene oil water emulsions adjuvants have been licensed for addition to human vaccine in 
the USA. Recently then, vaccine formulations containing Monophosphoryl lipid A (MPL), 
a TLR4 agonist, were approved for human use (Mbow et al.; Mosca et al., 2008) (Rappuoli 
et al., 2011). Aluminium based adjuvants (alum) have a good safe profile and increase the 
immune response to many vaccine antigens, such as that against tetanus, diphtheria and 
pertussis (Lindblad, 2004). Alum is generally effective at generating a strong antibody 
production to an antigen and it induces a Th2-type of immune response. The mechanisms 
of action of alum involve inflammation and recruitment of antigen-presenting cells, 
retention of antigen at the injection site, stimulation of antigen uptake, DCs maturation and 
T-cell activation (Coban et al., 2007). Although the efficacy of alum as adjuvant has been 
proved in a large number of vaccines, some limitations exist. For example, alum has failed 
to induce a satisfactory increase of the immune response in some vaccines, such as the 
influenza vaccine.  
MF59 is squalene oil water emulsions adjuvant. It is a Novartis proprietary adjuvant that 
was licensed in Europe for an influenza vaccine for the elderly (Fluad®). MF59 is a safe 
and strong adjuvant able to increase the immunogenic response to a large panel of antigens. 
Similarly to alum, MF59 treatment induces production of cytokines and chemokines and a 
strong cell recruitment of immune cells into the injection site.  
A current challenge is to identify vaccine adjuvants of various classes (cytokines, toll-like 
receptor ligands, etc.) with specific immune-modulating properties in order to tailor the 
immune response to certain pathological situations. Identification and development of new 
adjuvants is necessary because the small number of currently approved vaccine adjuvants 
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do not always elicit the desired protective immune response against different target 
pathogens (Mbow et al.). 
 
1.2.2.1 TLRs agonists as adjuvants 
In the past decade, most attention in the vaccine field has been placed on innate adjuvants 
that trigger pattern recognition receptors, such as TLRs. Triggering TLR stimulates the 
production of proinflammatory cytokines/chemokines and type I IFNs that increase the 
host’s ability to eliminate the pathogen. This innate immune response also supports the 
subsequent development of adaptive immunity, and thus can accelerate and enhance the 
induction of vaccine-specific responses. A large number of synthetic or natural TLR 
ligands have been explored as adjuvants in pre-clinical or clinical studies. Indeed, TLRs are 
the major pathogen sensors that modulate the host innate and adaptive immune systems and 
targeting TLR pathways represents a smart strategy to develop therapeutic vaccines. The 
role of TLRs as adjuvants is traditionally based on promoting DC maturation and antigen 
presentation. However, T cells also express functional TLRs and TLR signaling can 
directly modulate T cell function either as costimulatory or survival signaling. Clinical 
trials involving TLRs 2, 3, 4, 7/8 and 9 (Steinhagen et al., 2011) (Lahiri et al., 2008) (van 
Duin et al., 2006) support the broad conclusion that TLR ligands can be safe and effective 
vaccine adjuvants, with vaccines already licensed in the US, Europe and Argentina 
containing such ligands. 
At present, two improved adult HBV and HPV vaccines that use the TLR4 agonist MPL as 
the adjuvant have been approved (Rappuoli et al., 2011). MPL is a non-toxic derivative of 
the lipopolysaccharide (LPS) of Salmonella minnesota, and is a potent simulator of Th1 
responses. The effects of MPL as adjuvant include cytokine production, antigen 
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presentation and migration of APC to T cell area of draining lymph nodes, allowing for an 
efficient priming of naïve T cells (Boland et al., 2004).    
Another TLR’s agonist adjuvant is represented by the synthetic oligodeoxynucleotide 
containing unmethylated CpG motifs (CpG-ODN), used in both preclinical and clinical 
studies (Cooper et al., 2004b) (Cooper et al., 2004a). CpG-ODN acts through TLR9 
expressed by human plasmacytoid dendritic cells and B cells, inducing cellular activation 
and secretion of pro-inflammatory cytokines such as TNF-, IL-1, IL-6 and IL-12, but also 
IFN- and IFN-. This TLR9 agonist is an extremely efficient inducer of Th1 immunity, 
humoral and CTL responses and it is also able to mediate protection against infectious 
disease and allergic disorders. 
The TLR7/8 pathway, specialized in recognition of viral single stranded RNA molecules, 
has demonstrated promising pre-clinical results as a target for potential vaccine adjuvant. 
Small molecule agonists of TLR7, such as Imiquimod, or TLR7/8, such as Resiquimod, 
have been shown to improve the immunogenicity of a variety of anticancer and antiviral 
vaccines if adequately formulated or directly conjugated to protein antigens. In particular, 
Imiquimod is licensed as a topical therapy for treatment of HPV and basal cell carcinoma 
(Schulze et al., 2005) (Lebwohl et al., 2004). The exact mechanism of action of Imiquimod 
is unknown but it is thought that its activity as a TLR7 agonist leads to the expression of 
different cytokines such as IL-1, IL-6, IL-12, IFN- and TNF-; in turn, these cytokines 
stimulate or enhance both the innate immune system and the cell-mediated immune 
response, enhance migration of Langerhans’ cells from the dermis to regional lymph nodes, 
in addition to the induction of apoptosis in basal cell carcinoma. 
Multiple TLR2 ligands have undergone clinical testing. The most extensively studied was 
Pam3Cys linked to outer surface protein A of Borrelia burgdorferi that causes Lyme 
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disease (Steere et al., 1998). The vaccine, that in clinical trials induced a good Abs 
protection, was licensed by the FDA in 1998 for general use.  
 
1.2.2.2 TLR2 agonist SMIP2.1 as adjuvant 
The discovery that some compounds with adjuvant function are recognized by TLRs drove 
the interest of Novartis Vaccines in developing a novel family of vaccine adjuvants based 
on triggering the TLR pathways. In the 2007 Novartis Vaccines and Diagnostics has started 
a program with the goal to synthesize Small Molecules Immune Potentiators (SMIPs), 
synthetic compound with a chemical structure similar to TLRs ligands, to be tested as 
vaccine adjuvants. 
Using HEK293 cells expressing TLRs as well as luciferase reporter driven by the promoter 
of the NF-kB transcription factor, in my group it was identified a new scaffold of chemical 
compounds, the activity of which was TLR2-dependent. Among them, SMIP2.1 was 
selected for further characterization. SMIP2.1 is tryacilated lipopeptide, well-know TLR2 
agonist (Figure 4). SMIP2.1 showed a strong activation, TLR2 dependent, of innate 
immune cells, such as monocytes and dendritic cells in vitro. It was furthermore evaluated 
its possible use as adjuvant in vaccine formulations. My group showed that in vivo the 
lipopeptide was able to enhance the specific IgG titers against coadministered protein 
antigens (H1N1 Solomon Flu and Tetanus Toxoid), clearly demonstrating the adjuvant 
activity of our molecule (Unpublished data). 
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Figure 4. Structure of the SMIP2.1 (IUPAC Name = (4R)-4-[(2S)-2-[(2R)-3-{[(2R)-2,3-
bis(dodecanoyloxy)propyl]sulfanyl}-2-hexadecanamidopropanamido]butanamido]-4-
carbamoylbutanoic acid). 
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2. Aim of the research 
 
Efficient MHC presentation of vaccine proteins by APC is a prerequisite for induction of a 
protective immune response. Purified proteins, which are the component in most of the new 
vaccine, are usually presented by APCs mainly in class II MHC, since class I presentation 
of extracellular antigens is generally not very efficient. This results in an optional 
stimulation of CD4
+
 T cells but a poor CD8
+
 T cells priming, which is desirable for a 
vaccine against virus, intracellular bacteria or cancer. Cross-presentation is the process by 
which professional APCs are able to load peptides from a processed extracellular protein 
antigen into the class I molecules, triggering a CTL response. Adjuvants that specifically 
activate this pathway in the APCs are expected to improve the efficacy of vaccines for 
which a CTL response is of paramount importance. The discovery of immunization 
approaches that elicit a robust CD8
+
 T cell response by activation of the cross-presentation 
pathway along with a strong antibody response would represent a step forward in the 
development of vaccines against viral infections and tumors.  
Engagement of TLRs can increase cross-presentation, albeit the mechanism that underlies 
this phenomenon is still not clear. The ability of TLRs to recognize pathogens and 
modulate the host’s innate and adaptive immune system, and the discovery that some 
compounds with adjuvant function are recognized by TLRs, drove the interest in 
developing a novel family of vaccine adjuvant based on triggering the TLR pathway.  
The aim of my PhD project is to investigate if the novel compound, agonist of TLR2 
(SMIP2-1), can enhance cross-presentation of soluble antigens to CD8
+
 T cells. SMIP2-1 is 
a novel synthetic lipopeptide, identified through two cell-based high throughput screens 
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performed at the Genomic Institute of Novartis Research Foundation, and is currently under 
evaluation as vaccine adjuvant by Novartis Vaccines. Previous in vitro and in vivo 
experiments demonstrated that this new compound can induce activation of the innate 
immune system via a TLR2-dependent mechanism, inducing maturation of antigen 
presenting cells and eliciting a strong antibody response against Flu and tetanus toxoid 
antigens (unpublished data). 
Both in vitro and in vivo data show that SMIP2-1 can enhance CD8
+
 T cells activation, 
along with a robust CD4
+
 T cell response, a feature that can be exploited in the design of an 
effective adjuvant for antitumor and antiviral vaccines. 
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3. Materials and methods 
 
3.1 Mice and immunization 
Female, 8 weeks old C57Bl/6, OT-I and B6-Ly5.2 (Charles River) mice were used for 
immunogenicity studies approved by the institutional review committees. Animals were 
immunized intra-muscularly in both quadriceps muscle with 50l dose per leg with 
Dulbecco’s Phosphate Buffered Saline (DPBS 1x, GIBCO) alone, 10 or 25 µg of OVA 
protein (EndoGradeTM Ovalbumin, Hyglos) dissolved in DPBS and OVA in the presence 
of SMIP2.1 or Pam3CSK4. SMIP2.1 was used at 10 or 100 ug/dose/mouse. Pam3CSK4 
was purchased from Invivogen (tlrl-pms) and used at 10ug/dose/mouse. Six to ten mice per 
group were used in different experiments. Mice were immunized at days 0, 21 and 35. 
Blood samples for antibody titers analysis were collected 2 weeks after the second and the 
third immunization, and serum prepared by centrifugation. For K
b
/OVA257–264 tetramer 
analysis, blood was collected 1 week after each immunization in a tube with heparin. 
 
3.2 Cell Culture 
All cultured cells were grown at 37°C in a humidified environment containing 5% CO2. 
Mouse cells from lymph nodes and spleens were cultured in complete RPMI 1640 
(GIBCO) containing 100 U/ml penicillin, 100 µg/ml streptomycin, 2mM glutamine 
(GIBCO), 2×10
-5
M 2-mercaptoethanol (Sigma) and 5% heat-inactivated fetal calf serum 
(Hyclone). 
Human PBMC were isolated from buffy coats of healthy donors using Ficoll gradient and 
cultured in complete RPMI 1640 (GIBCO) supplemented with 100 U/ml penicillin, 100 
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µg/ml streptomycin, 2mM glutamine (GIBCO), 1% of non-essential amino acids (GIBCO) 
and 5% heat-inactivated AB human serum (Euroclone). 
 
3.3 OT-I Tcell proliferation in vitro: [
3
H]Thymidine incorporation 
CD11c DCs were isolated from spleens of C57Bl6 mice by cell sorting using FACS Aria 
sorter. Sorted DCs were plated at 25.000 cells/well in a 96 well plate and loaded with 
medium alone or with medium containing OVA (10ug/ml) or OVA + SMIP2.1 (10uM) for 
4 hours. Cells were then washed twice with PBS and incubated in a ratio 1:5 with CD8
+
 T 
cells, purified form spleen and total lymph nodes of OT-I mice using a Miltenyi CD8a
+
 T 
cell isolation kit,. Cells were pulsed with [
3
H]Thymidine (Amersham Biosciences) at 
0.5Ci/well for the last 18h of a 72h-culture, then harvested onto filter plates (Packard 
Instruments). [
3
H]Thymidine uptake was determined using a Top Count NXT β counter 
(Packard Instruments). 
 
3.4 In vivo proliferation of OVA-specific T cells 
CD8
+
 T cells were immunomagnetically separated from spleen and total LN of OT-I mice, 
accordingly to manufacturer instructions (Miltenyi Biotec). The efficiency of enrichment 
was routinely 85−95%, as determined by flow cytometry. Cells were incubated with CFSE 
 dark and CFSE staining was quenched by the addition of 
5 ml of FBS. Cells were washed exstensively with PBS and 1×10
6
 CFSE-labeled OT-I cells 
were injected intravenously into Ly5 mice (100ul/mouse). The day after, mice were 
immunized as indicated. Proliferation of adoptively transferred OT-I cells in the inguinal 
lymph nodes was quantified 48 h after the immunization by determining the number of 
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CFSE
low
 OT-I cells by flow cytometry. Total cells were stained with CD3 PE, anti CD8 
V500, CD44 APC (BD Pharmingen) and CD45.2 Alexa 700 (eBioscience). 
 
3.5 Tetramer analysis of OVA-specific CD8
+
 T cells 
Peripheral blood samples, collected from the saphenous vein at the time points indicated, 
were stained with APC-conjugated K
b
/OVA257–264 tetramer reagent (Beckman Coulter), 
combined with surface staining using anti-CD8 PE Texas Red, anti CD3 PerCP Cy5.5, anti 
CD4 V500, anti-CD44 V450 (BD Pharmingen) for 30min at RT. Samples were lysed and 
fixed (iTAG MHC tetramer lyse and fixative (Beckman Coulter). Cells were analyzed at 
the cytofluorimeter collecting a minimum of 2,5x10
5
 events. 
 
3.6 In Vivo Killing Assay 
A single-cell suspension of splenocytes from naïve B6-Ly5.2 was prepared, and red cells 
were lysed. Cells were split into two aliquots and labeled with either 1 μM or 0.1 μM CFSE 
Cells were then resuspended at a concentration of 1 × 10
7
 cells/ml in cRPMI containing 
10 μg/ml OVA257–264 peptide (CFSE
high
) or an irrelevant control peptide derived from 
HCMV pp65protein (CFSE
low
) and incubated for 30 min at 37 °C. Unbound peptide was 
removed by three washes in PBS, and labeled cells were resuspended at a 1:1 ratio in PBS 
(50 × 10
7
 cells/ml). 100 μl of cell suspension was delivered intravenously into the tail vein 
of C57Bl/6 mice that had been immunized 7 days before as described above. Twenty-four 
hours after target cell implant, mice were euthanized and splenocytes preparations were 
stained with CD45.2 Alexa 700 and assayed for the presence of CFSE-labeled cells by flow 
cytometry. The percentage of specific lysis of fluorescent target cells in each group was 
calculated according to the formula: [1-(mean of CFSE ratio of mice immunized with 
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adjuvant / mean of CFSE ratio of mice immunized with PBS)] x 100, as described by 
Ingulli (Ingulli, 2007). 
 
3.7 Determination of Antigen-Specific Antibody titers by ELISA 
Anti-Ovalbumin specific total immunogloblulin G (IgG) antibodies were measured by 
ELISA performed on sera, using a standard reference serum. Maxisorp plates (Nunc) were 
coated over-night at 4°C with 50 µg/ml of OVA in carbonate buffer, washed with PBS 
0,05% Tween-20 and blocked for 1 h at 37°C with 100 µl of PBS 1% BSA. Serum samples 
and serum standard were serially diluted in PBS + 1% BSA + 0,05% Tween-20 and 
transferred into OVA coated-blocked plates. Antigen-specific IgG, were detected with 
alkaline phosphatase-conjugated goat anti-mouse IgG, (Southern Biotech). Plates were 
washed and the substrate 4-Nitrophenyl phosphate disodium salt hexahydrate (SIGMA) 
added Color reaction was stopped by addition of H2SO4 and measured with SpectraMax 
(Molecular Devices) reader by determining OD at 450 nm. Antibody titers were calculated 
using a 4-parameter interpolation fit as the reciprocal of the dilution of each serum sample.  
 
3.8 E.G7 tumor challenge experiments 
C57BL/6 mice were immunized two times as indicated. 7 days after the second 
immunization, mice were subcutaneously inoculated in the right flank with 2,5 × 10
5
 E.G7-
OVA cells (ATCC) in 100µl of PBS. Mice were monitored every 2-3 days. Tumor bearing-
mice were euthanized when mice became moribund in accordance with Animal Care 
guidelines. 
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3.9 Confocal analysis of LNs cryosections 
OCT-  glass 
slides, and quickly air dried. Slides were fixed in a 4% formaldehyde solution on ice and 
blocked with PBS + 3% BSA + 1% saponin. Slides were then stained with CD169 FITC 
(Serotec) and CD45R. Slides were mounted with ProLong gold antifade reagent 
(Invitrogen), and imaged on a LSM 710 microscope (Zeiss). 
 
3.10 Donors 
Buffy coats from healthy donors were obtained from the Blood Transfusion Section, 
Empoli Hospital. Informed consent was obtained before all blood donations. The study 
protocol was approved by the Novartis Research Center ethical committee and conforms to 
the ethical guidelines of the 1975 Declaration of Helsinki. 
 
3.11 Stimulation with CMV peptide for activation of antigen-specific CD8
+
 T cells 
PBMC isolated from healthy blood donors were assayed for the positivity to CMV using 
CMV-specific tetramers (Bekman Coulter) and then stimulated with a mix of peptides 
derived from pp65 protein (JPT Peptide Technologies) at 3ug/ml for each peptide. Cells 
were co-cultured for 14 days, replacing fresh medium when required and adding IL-2 at 
days 4, 7, 10. At day 14, autologous PBMC were plated in a 96 well plate at 500.000 
cells/well in complete medium and loaded with pp65 protein (Miltenyi Biotec) at 50 µg/ml 
with or without SMIP2.1 at 15 µM. After 2 hours, cells were washed twice and co-cultured 
over-night with the expanded CMV specific CD8
+
 T cells population in a ratio 1:1 in the 
presence of 5 µg/ml secretion inhibitor BFA (Sigma).  Cells were then fixed, stained for 
intracellular cytokine production -Cy5.5 and 
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CMV-
production in the effector OT-I T cells was used as a measure of the level of Ag cross-
presentation by DCs. 
 
3.12 Antibodies and flow cytometry 
Cells were stained with combinations of the following antibodies: Ly6C-FITC, CD11b-PE-
Cy7, CD11c-APC, F4/80 PacificBlue, CD11c-APC-AlexaFluor750 (all from eBioscience). 
Flow cytometry was performed on FacsCanto or FACS LSRII instruments using DIVA 
software (Becton Dickinson) and data were analyzed using Flowjo software (Treestar Inc.).  
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4. Results  
4.1 SMIP2.1 induces cross-presentation in vivo  
In order to test the potential of SMIP2.1to induce cross-presentation of soluble antigen in 
vivo, we assessed its effects on antigen-induced expansion of CD8
+ 
T cells. We used TCR 
transgenic OT-I CD8
+ 
T cells that recognize an OVA-derived peptide and that have been 
extensively used in many in vivo and in vitro experimental settings to investigate cross-
presentation (Hogquist et al., 1994). We compared the efficacy of our compound with the 
TLR2 ligand benchmark N-Palmitoyl-S-cysteinyl-seryl-4lysyl (Pam3CSK4). In a first 
experiment, we adoptively transferred CFSE-labeled OT-I CD8
+
 T cells in congenic Ly5 
mice and the day after we immunized the recipient mice with PBS alone, OVA, OVA + 
SMIP2.1 or OVA + Pam3CSK4. We determined OT-I proliferation in draining lymph 
nodes after 48 h by flow cytometry using a mix of antibodies as described in Fig.1.  
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Figure 1. Gating strategy for defining proliferating CD8
+
 T cell population in the adoptive 
transfer experiment. Cells isolated from draining LN have been stained with the indicated 
antibodies (CD3
 
PE, CD8
 
V500, CD45.2
 
Alexa 700, CD44 APC) to identify the adoptively 
transferred proliferating CD8
+
 T cell population (CFSE
low
 CD8
+
 T cells). The inset numbers 
represent the percentage of the gated cells in the respective gating step. FCS-A, forward scatter; 
SSC-A, side scatter; SSC-W, width scatter. 
 
The magnitude of OT-I CD8
+
 T cells expansion was used as a measure of the level of OVA 
cross-presentation. Analysis of CFSE dilution revealed an increased proliferation of OT-I 
cells in mice immunized with the protein in the presence of SMIP2.1 (48,9% dividing OT-I 
cells in the OVA + SMIP2.1 condition vs 24,5% in the not adjuvanted OVA condition) 
(Fig2A and B). We observed a comparable CD8
+
 T cells expansion in mice immunized 
with OVA + Pam3CSK4 (43,8% dividing OT-I cells in the OVA + Pam3CSK4 condition 
vs 24,5% in the not adjuvanted OVA condition). 
 
A 
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B 
 
 
Figure 2. SMIP2.1 induces cross-presentation in vivo. Congenic Ly5 mice, injected in the tail 
vein with CFSE-labeled OT-I CD8
+
 T cells, were immunized with PBS alone, OVA (10 µg/mouse), 
OVA + SMIP2.1 (10 µg/mouse), OVA + Pam3CSK4 (10 µg/mouse). A, One representative plot for 
each group is shown to compare proliferation of adoptively transferred OTI cell in PBS immunized 
mice (red curve) to OVA, OVA + SMIP2.1 and OVA + Pam3CSK4. B, The graph shows the 
percentage of proliferating CD8
+
 T cells (mean ± SD). Representative data of three independent 
experiments are shown. 
 
 
We then tested the ability of SMIP2.1 to induce cross-presentation in a more physiological 
vaccination animal model. We immunized C57Bl/6 mice at days 1, 21, 35 with PBS alone, 
OVA, OVA + SMIP2.1 or OVA + Pam3CSK4. We collected blood samples, sera and 
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spleens for further analysis. Priming of CTLs, induced by cross-presentation of OVA 
protein to naive CD8
+
 T cells, was evaluated measuring the percentage of CD8
+
 T cells 
positive for the K
b
-OVA257-264 tetramer, in the peripheral blood 7 days after the   1
st
 and the 
2
nd
 immunization (Fig3A). No expansion of Ag-specific CD8
+
 T cells was observed in the 
absence of TLR2 agonists. Addition of SMIP2.1 or Pam3CSK4 strongly enhanced the 
frequency of OVA primed CD8
+
 T cells and the magnitude of the response increased 
significantly after the second immunization (Fig3B). SMIP2.1 proved to be more potent 
than the benchmark Pam3CSK4. 
 
A 
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B 
 
 
Figure 3. SMIP2.1 induces cross-presentation in vivo. C57Bl/6 mice were immunized twice with 
PBS alone, OVA (25 µg/mouse), OVA + SMIP2.1 (10 µg/mouse) or OVA + Pam3CSK4 (10 
µg/mouse) and bled from the tail vein 7d days post 1
st
 and 2
nd
 immunization. Blood cells were 
stained with K
b 
/OVA257-264 tetramer to measure the frequency of OVA specific CD8
+
 T cells. A, 
Gating strategy used for defining frequency of OVA specific CD8
+
 T cells. Blood cells have been 
stained with the indicated antibodies (CD3
 
PerCP Cy5.5, CD8
 
PE Texas Red, CD4 V500, CD44 
V450). B, The histogram show the percentage of OVA specific CD8
+
 T cells. Data shown is 
representative of two different experiments.  
 
 
7 days post 3
rd
 immunization, mice were sacrificed and splenocytes were re-stimulated ex 
vivo with PBS alone or with OVA257-264 peptide. We compared the ability of splenic CD8
+
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production by flow cytometry staining (Fig4). We showed that splenic CD8
+
 T cells of 
mice immunized with SMIP2.1 or Pam3CSK4 were able to induce a strong pro 
inflammatory cytokines production when re-stimulated in vitro. Taken together, these data 
demonstrate that SMIP2.1 was able to expand the number of functionally active CD8
+
 T 
cells even more efficiently than Pam3CSK4, as shown by the increased frequency of CD8
+
 
T cells and pro-inflammatory cytokine production.  
 
 
 
Figure 4. SMIP2.1 induces cross-presentation in vivo. C57Bl/6 mice were immunized twice with 
PBS alone, OVA (25 µg/mouse), OVA + SMIP2.1 (10 µg/mouse) or OVA + Pam3CSK4 (10 
µg/mouse). Spleens of C57Bl/6 immunized mice were collected 7 days after the 3
rd
 immunization 
and spelonocytes were pulsed with OVASIINFEKL peptide (3 µg/ml) or with PBS alone, as negative 
control, for 6h. Cells were then fixed and stained for IFN and TNFα.  
 
SMIP2.1 has been previously tested in vivo as adjuvant in two vaccines against tetanus and 
influenza in mouse. In both systems, the compound was able to significantly increase the 
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antibody titer against the vaccine antigen (Manuscript in preparation). Also in OVA 
immunized mice, we demonstrated that SMIP2.1 is more potent than Pam3CSK4 inducing 
high OVA specific total IgG titer, measured in the serum two weeks after the 3
rd
 
immunization (Fig5). 
 
 
 
Figure 5. SMIP2.1 boosts antibody production. Sera from immunized mice were collected 2 
weeks after the 3
rd
 immunization and total IgG titer was measured by ELISA. Data are 
representative of 2 different experiments.  
 
 
4.2 SMIP2.1 induces antigen-specific CTL activity in vivo 
We then evaluated if antigen-specific CD8
+ 
T cells, induced by immunization with OVA 
protein plus SMIP2.1, were functional in terms of cytolytic activity. To test the CTL 
activity, we used an in vivo cytotoxicity assay wherein C57Bl/6 mice were immunized with 
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PBS alone, OVA, OVA + SMIP2.1 or OVA + Pam3CSK4. Seven days after the 
immunization, we injected mice i.v. with CFSE labeled splenocytes, isolated from a 
congenic Ly5 mouse, pulsed with either OVASIINFEKL peptide or an irrelevant control 
peptide and mixed in a ratio 1:1 prior to injection. The SIINFEKL-loaded splenocytes were 
labeled with 1 M CFSE and are identified as the CFSEhigh target population, while the 
control splenocytes, labeled with an irrelevant peptide, were labeled with 0.1M CFSE and 
are identified as the CFSE
low
 cell population. Twenty-four hours after target cell implant, 
we sacrificed mice and assayed the splenocytes for the presence of CFSE-labeled cells by 
flow cytometry. The ratio between the two cell populations correlates with cytolitic activity 
(Fig6).  
 
                                                                                                                                       Results 
48 
 
Figure 6. Experimental scheme describing the cytotoxic assay in vivo. Seven days after the 
immunization, C57Bl/6 mice were injected i.v. with CFSE labeled splenocytes, isolated from a 
donor mouse, pulsed with either OVASIINFEKL peptide or an irrelevant control peptide and mixed in a 
ratio 1:1 prior to injection. The SIINFEKL-loaded splenocytes were labeled with 1 M CFSE 
(CFSE
high
 target population), while the control splenocytes, labeled with an irrelevant peptide, were 
labeled with 0.1M CFSE (CFSElow control population). Twenty-four hours after target cell 
implant, we sacrificed mice and assayed the splenocytes for the presence of CFSE-labeled cells 
populations by flow cytometry.  
 
The killing activity towards peptide coated target cells is strongly increased when mice are 
immunized with OVA plus TLR2 agonists compared to mice immunized with OVA alone 
(Fig7A and B) and SMIP2.1 is even more efficient than Pam3CSK4. The OVA-specific 
CTL activity correlates with the expansion of OVA specific CD8
+
 lymphocyte population, 
as demonstrated by the percentage of OVASIINFEKL tetramer positive CD8
+ 
T cells in 
peripheral blood in mice immunized with adjuvanted OVA (Fig7C). 
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Figure 7. SMIP2.1 induces antigen-specific CTL activity in vivo. C57Bl/6 mice were immunized 
with PBS alone, OVA (25 µg/mouse), OVA + SMIP2.1 (10 µg/mouse) or OVA + Pam3CSK4 (10 
µg/mouse). After seven days, mice were implanted i.v. with syngeneic splenocytes loaded with two 
different concentrations of CFSE and pulsed with either OVASIINFEKL peptide (CFSE
high
) or an 
irrelevant control peptide (CFSE
low
) in a ratio 1:1. Twenty-four hours later, CTL response was 
assessed in draining LN measuring the presence of CFSE
high
 target cells by flow cytometry. A, In 
the panel are reported the histograms showing the CFSE content for each mouse (3 or 5 mice/group) 
in OVA, OVA + SMIP2.1 and OVA + Pam3CSK4 immunized groups. B, The graph shows the 
percentage of specific lysis of fluorescent target cells in OVA, OVA + SMIP2.1 and OVA + 
Pam3CSK4 immunized groups calculated as described in M&M. C, A peripheral blood sample was 
obtained from mice prior to cells infusion and cells were stained with K
b 
/OVA257-264 tetramer to 
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measure the frequency of OVA specific CD8
+
 T cells. The percentage of K
b 
/OVA257-264 tetramer
+
 
CD8
+
 T cells in mice immunized with PBS was subtracted to the other groups. 
 
We next assessed if CD8
+
 T cells elicited by immunization with OVA plus SMIP2.1 were 
able to recognize and kill tumor cells, evaluating the antitumor effect of SMIP2.1 in mice 
bearing E.G7-OVA tumors. Mice were immunized twice with PBS alone, OVA, OVA + 
Pam3CSK4 10 µg/mouse or OVA + SMIP2.1 at 10 µg/mouse. 7 days after the second 
immunization, mice were subcutaneously inoculated with OVA-expressing E.G7 tumor 
cells and tumor growth was monitored. 47 days after E.G7-OVA tumor cells inoculation, 
the 80% of non-vaccinated and OVA-immunized mice died (20% of survival). In mice 
immunized with OVA + TLR2 agonists the rate of survival was considerably increased. In 
mice immunized with OVA + Pam3CSK4, 5 mice out of 10 developed tumor (50% of 
survival) while in mice immunized with OVA +  SMIP2.1 at 10 µg/ml only 3 out of 10 
mice developed tumor and were sacrificed (70% of survival) (Fig8). We can then conclude 
that in this prophylactic setting immunization with OVA + SMIP2.1 results in a strong 
tumor growth inhibition. 
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Figure 8. SMIP2.1 induces antigen-specific CTL activity in vivo. C57Bl/6 mice were immunized 
twice with PBS alone, OVA (25 µg/mouse), OVA ± SMIP2.1 (10 µg/mouse) or OVA + Pam3CSK4 
(10 µg/mouse). Seven days after the second immunization, mice were implanted s.c. with OVA-
expressing E.G7 tumor cells and mice were monitored for tumor growth. The graph shows the 
percentage of tumor-free mice 47 days after tumor cells implantation. Mice were euthanized when 
moribund. Representative data of three independent experiments are shown. 
 
 
4.3 SMIP2.1 induces antigen deposition 
The mechanisms by which adjuvants enhance immunogenicity of the antigens have been 
investigated for several years. Some papers show that they increase Ag depot, prolonging 
the persistence of antigen in vivo (Seubert et al., 2008) (Schijns and Tangeras, 2005). To 
explore the mechanism by which TLR2 agonist works as a vaccine adjuvant, we examined 
the possibility that SMIP2.1 increases the antigen depot in lymphoid organs. We 
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immunized mice with fluorescent-labeled OVA in the presence or not of SMIP2.1 and we 
collected the draining LN 24 hours after the immunization to detect the antigen deposition. 
We analyzed the tissues by confocal microscopy and found that mice immunized with 
OVA plus SMIP2.1 show a slightly increase in the deposition of the OVA antigen 
compared to mice immunized with OVA alone (Fig9). Therefore, also SMIP2.1 increases 
the amount of captured antigen.  
 
 
Figure 9. SMIP2.1 increases Ag deposition in the draining LN. C57Bl/6 mice were immunized 
with PBS alone, OVA A555 (25 µg/mouse) ± SMIP2.1 (100 µg/mouse) and draining LN were 
collected 24h later. 8µm thick cryosections of draining LNs were stained for CD169 (green) and 
CD45R (blue) and observed under a confocal microscope. The picture (magnitude 40x) shows the 
OVA antigen deposition (red) only in mice immunized with OVA + SMIP2.1. Bar represents 20 
µm.  
 
 
We then analyzed if SMIP2.1 has an effect in the induction of antigen uptake by a specific 
cell type. To this aim, we collected draining LNs from fluorescent-OVA immunized mice 
and we analyzed antigen content in different cell types by FACS using CD11b, CD11c, 
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MHC II, CD8, F4/80, Ly6C cell markers to identify CD8α- DCs (Cd11bhigh, CD11c+, 
CD8-, MHC II+), CD8α+ DCs (Cd11bhigh, CD11c+, CD8+, MHC II+), macrophages 
(Cd11b
+
, F4/80
high
), inflammatory monocytes (Cd11b
high
, CD11c
-
, Ly6C
high
) and B cells 
(Cd11b
-
, CD11c
+
, MHC II
+
). In agreement with the confocal analysis, SMIP2.1 induces an 
increase in OVA uptake and this is evident in all cell subtypes analyzed (Fig10). 
 
 
 
Figure 10. SMIP2.1 increases Ag deposition in the draining LN. Groups of 3 mice were 
immunized with PBS alone, OVA A647 (25 µg/mouse) ± SMIP2.1 (100 µg/mouse). Draining LN 
were collected 24h later and analyzed in pool by FACS to identify specific cells types and Ag-
content. The graph shows the number of OVA A647
+
 cells per 1x10
6
 total cells. The data shown are 
representative of two independent experiments. 
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4.4 SMIP2.1 induces cross-presentation in vitro 
In mice, two subpopulations of dendritic cells are discriminated by the expression of the 
CD8 marker, with different functions. CD8α+ CD11c+ DCs may have the unique ability to 
cross-present (Belz et al., 2004) (Shortman and Heath, 2010) (Heath and Carbone, 2001) 
whereas in humans, cross-presenting DC are CD141
+
 (1977)(BDCA3
+
). However, there are 
evidence showing that both CD8α+ and CD8α- CD11c+ are able to present exogenous 
antigen to CD8
+ 
T lymphocytes with equivalent efficacy when opportunely stimulated (den 
Haan and Bevan, 2002) (Moron et al., 2002). Since immunization with TLR2 agonist 
increases the antigen uptake by both CD8α+ CD11c+ and CD8α- CD11c+ dendritic cells, we 
assessed the potential of SMIP2.1 to enhance cross-presentation ability of both CD11c
+
 
DCs subpopulations, evaluating its effect on antigen-induced expansion of CD8
+ 
T cells in 
vitro.  
CD8α+ CD11c+ and CD8α- CD11c+ dendritic cells were purified by cell sorting from the 
spleen of a C57Bl/6 mouse and loaded with soluble low endotoxin OVA protein, in the 
presence or not of SMIP2.1, for 4 hours. After  washing, DCs were co-cultured for 72 hours 
with OT-I CD8
+
 T cells, that were previously immunomagnetically isolated from the spleen 
and total lymph nodes of OT-I transgenic mice. As assessed by thymidine incorporation, 
both DC populations pulsed with OVA and SMIP2.1 induced a greater OT-I proliferation 
as compared to DCs pulsed with OVA alone (Fig11). 
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Figure 11. In vitro proliferation of OT-I cells to OVA protein. CD8+ CD11c+ and CD8- 
CD11c
+
 DCs were purified by cell sorting from the spleen of C57Bl/6 mice and cultured with 
medium alone, OVA (10 µg/ml) ± SMIP2.1 (10 µM) for 4 hours. After washing, DCs were co-
cultured for 60 hours with purified OT-I CD8
+
 T cells. 
3
H thymidine (0,5µCi/well) was added and 
proliferation of CD8
+
 OTI T cells was checked after 12 h by liquid scintillation counting. Data 
indicate counts per min (CMP) and expressed as mean ± SEM of triplicate wells. Values of CPM 
from cells stimulated with medium alone were subtracted from the other conditions. 
 
 
4.5 In human experiment 
To test if SMIP2.1 is able to induce cross-presentation also in human cells, we co-cultured 
PBMCs isolated from a HCMV seropositive donor with autologous CD8
+
 T cells 
recognizing a mix of peptides from the HCMV protein pp65. CMV is an herpes simplex 
virus and CD8
+
 T cell response to CMV antigens is detectable in most CMV-seropositive 
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donors (Harari et al., 2004). We set up a cell-based in vitro model in which we evaluate the 
efficiency of cross-priming with the purified recombinant protein pp65 in human peripheral 
blood mononuclear cells (PBMC), using a flow cytometry assay to detect intracellular 
cytokine production by CD8
+
 T cells.  
PBMC from CMV seropositive donors were isolated by a density gradient centrifugation in 
Ficoll and stimulated with a library of pp65 peptides to expand the CMV-specific memory 
CD8
+
 T cell population, as identified by tetramer staining (Fig12).  
 
Figure 12. CMV tetramer staining on human peripheral blood: example. PBMC from a CMV 
seropositive donor were stained with 5 CMV tetramers, able to recognize different TCR specific for 
5 immunodominant peptides of the CMV pp65 protein. The inset numbers represent the percentage 
of the CMV tetramer
+ 
cells for the different tetramers. In the example shown, the donor has the 
0,806% of CD8
+ T cells specific for the CMV tetramer 5. PBMC were stimulated with a library of 
pp65 peptides to expand the CMV-specific memory CD8
+
 T cell population, as demonstrated by 
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tetramer staining 12 days later showing an increase in the percentage of CMV tetramer 5 specific 
CD8
+
 T cells (2.08 vs 0,8%). 
 
The CMV-specific CD8
+
 T cells were then restimulated with autologous APC that were 
previously loaded with pp65 CMV protein with or without SMIP2.1. After 4 hours of 
stimulation, cells were fixed, permeabilized and stained with CD3, CD8, IFN antibodies 
and CMV-tetramers to detect IFNµ production by CMV-specific CD8
+ 
T cells.  
In the experiments shown in Figure 13, APCs pulsed with pp65 antigen and stimulated 
with SMIP2.1 were found to cross-present the protein more efficiently than APCs pulsed 
with pp65 antigen alone, as it is shown by their ability to stimulate a higher frequency of 
IFNµ producing CMV-specific CD8
+
 T cells.  
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Figure 13. SMIP2.1 induces cross-presentation in vitro in human cells. PBMC isolated from a 
CMV seropositive donor were pulsed in vitro as indicated for 2 hours, washed and co-cultured for 4 
hours with an expanded CMV specific CD8
+
 T cell population. Production of IFN by CD8+ T cells 
was quantified by intracellular cytokine staining assay and is shown as the percent of CD3
+
, CD8
+
, 
IFN+ pp65 CMV tetramer+ CD8+ T cells.  
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5. Discussion 
The failure to stimulate a CTL response is a major impediment to the development of 
subunit vaccines. Exogenous proteins in vaccines formulation are poor inducers of CD8
+
 T 
cell immunity, as they are captured by APCs and presented to CD4
+
 T cells, leading to a 
good humoral response but poor cellular immunity. The discovery of TLRs can modulate 
the host innate and adaptive immune response has triggered interest in studying this class of 
receptors to identify potential vaccine adjuvants and therapeutic agents. 
In this study, we demonstrate that a soluble protein can be introduced into the class I MHC 
Ag-restricted processing and presentation pathway by the use of the SMIP2.1 adjuvant in 
order to induce a CD8
+
 T cell response. SMIP2.1 is a tryacilated lipopeptide, well-know 
TLR2 agonist, identified by two High-Throughtput Screenings performed at the Genomic 
Institute of the Novartis Research Foundation in San Diego. This compound is under 
evaluation as vaccine adjuvant by Novartis.  
Using Ovalbumin (OVA) as model antigen, our findings show that mice immunized with 
OVA protein and TLR2 adjuvant greatly increase OVA-specific CD8
+
 T cell priming.  
Moreover, using an OVA expressing tumor model, we show that the CTL response induced 
by the SMIP2.1 adjuvanted vaccine is able to inhibit tumor growth. This evidence suggests 
that SMIP2.1 could be extremely useful as a component in subunit vaccines, especially 
when a CTL response is required. Different papers have previously shown that TLR2 
agonists act as antitumor agents (Ingale et al., 2007) (Garay et al., 2007) (Brandau and 
Suttmann, 2007) (Murata, 2008) but they might also promote tumor growth in some tumor 
models (Kim et al., 2009) (Huang et al., 2007). Others have also described a role for Toll 
like receptor-2 to abrogate regulatory T cell function (Piccioli et al., 2007) (Sutmuller et al., 
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2006). In this work, we clearly show that SMIP2.1 is an inhibitor of tumor growth, and, 
even if we have shown a direct effect on the cross-priming of CD8
+
 T cells, as well as 
directly enhance CD4
+
 and CD8
+
 T cells function (Unpublished data) we still haven’t 
investigated if it has a direct effect on regulatory T cells, as demonstrated by Zhang and co-
workers for BCG (Zhang et al., 2011).  
Mechanisms by which adjuvants could enhance the immunogenicity of Ags remain unclear 
and under debate. Some studies implicate the formation of Ag depots as the underlying 
cause. These findings have led to the proposal that adjuvants enhance the immune response 
through prolonging the persistence of Ag in vivo. Moreover, Ag aggregation could affect 
the pathway and efficiency of uptake by APCs. We have shown that SMIP2.1 increases Ag 
deposition in the draining lymph node of the site of injection, and the amount of Ag 
presenting cells that have taken up the antigen. Due to the observation that after 
immunization with adjuvanted vaccine not only DCs but also other cell populations in the 
draining LN increase their ability to take up the antigen, we wondered if this increased 
uptake could result in enhanced cross-presentation ability. Different papers show in mice 
that only CD8+ CD11c+ DCs are especially able to cross-present. The superior ability of 
CD8+ DCs in cross-presenting cell-bound antigens may be reflected by their unique 
ability to phagocyte dead cells (Schulz and Reis e Sousa, 2002) (Iyoda et al., 2002). 
However, they are also able to cross-present soluble antigens. Since the CD8+ DC 
population represents only the 20% of the conventional DCs in the mouse spleen (Shortman 
and Heath, 2010), the possibility to induce an MHC I-mediated presentation to CD8
+
 T 
cells in CD8- DC represents a big challenge. If rightly stimulated, also CD8- DC can 
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cross present and our data show that stimulation with SMIP2.1 activates cross-presentation 
in CD8- DCs subsets. 
Cross-presentation has been extensively described in different animal models, while very 
little reports have been published on human cells. Sub-populations of human DCs have 
been targeted through C-like lectin receptors with the aim to increase their ability to cross-
present (Schreibelt et al., 2012) (Bonifaz et al., 2004) (Idoyaga et al., 2011) and recently, 
human CD141
+
 DCs have been identified as the human counterpart of the murine CD8+ 
DCs, the most effective in antigen cross-presentation (Bachem et al., 2010) (Poulin et al., 
2010) (Jongbloed et al., 2010). In this report, we show that an adjuvant is able to increase 
cross-presentation in human PBMCs, without targeting neither a specific subpopulation of 
DCs, nor using a conjugated antigen, corroborating the mouse data in which we do see 
enhanced cross-presentation ability in different cell populations. However, additional 
studies are required to identify which cell type is specifically targeted by SMIP2.1 in order 
to enhance cross-presentation. 
In conclusion, in this work we showed that SMIP2.1 induces a strong CTL response after 
only one immunization, confirming that the compound is potent adjuvant for priming 
peptide-specific CTL responses. Furthermore, only small amount of the lipopeptide is 
needed to cause robust humoral and cell-mediated immune response (10 nmoli lipopeptide 
per animal) thus avoiding possible toxic effects associated with the use of an adjuvant. 
Although TLR ligands are effective at promoting vaccine efficacy, a better immune 
response is generated when both TLR ligand and Ag are covalently (Ozinsky et al., 2000) 
(Prajeeth et al., 2010) (Shirota et al., 2001) or electrostatically (Chua et al., 2011) linked. 
However, these approaches have several drawbacks in the large-scale production of 
                                                                                                                                 Discussion 
63 
 
vaccines. Antigen and lipopeptides conjugation can be chemically challenging because they 
are dissolved in aqueous and lipid phases, respectively. Moreover, both techniques might 
have stability problems. Jackson’s group has recently shown that electrostatic ligation of 
soluble proteins to the TLR2 agonist dipalmitoyl-S-glyceryl-cysteine (Pam2Cys), a 
diacetylated lipopeptide, elicits a good CD8
+
 T cell response. Since our compound is a 
triacetylated lipopeptide, we used the triacetylated lipopeptide Pam3CSK4 as TLR2 
benchmark.  We showed that Pam3CSK4 is able to induce a good immune response 
without the need to be coupled to the antigen. Using HEK293 stable transfected with TLR2 
as well as primary immune cells (unpublished data), we observed that TLR2 benchmark 
Pam3CSK4 and SMIP2.1 have a similar potency as TLR2 activators but, when we 
compared the ability of the TLR2 agonists to cross-present in vivo, we observed that our 
compound works better that Pam3CSK4 in inducing antibody and CTL response.  
This study show that SMIP2.1 can generate antigen specific CTL, along with a robust CD4
+
 
T cells activation, a feature that can be exploited in the design of an effective adjuvant for 
antitumor and antiviral vaccine. 
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